Connect with us
DAPA Banner

Crypto World

Novo Nordisk (NVO) Stock Drops 15% After CagriSema Fails to Beat Eli Lilly’s Zepbound

Published

on

NVO Stock Card

TLDR

  • Novo Nordisk stock fell 15% after CagriSema failed to prove non-inferiority to Eli Lilly’s tirzepatide in an 84-week trial.
  • CagriSema delivered 23% weight loss vs. 25.5% for tirzepatide — missing its primary endpoint.
  • The stock hit its lowest level since June 2021, down nearly 50% over the past year.
  • Novo’s CEO remains confident in CagriSema, citing its potential as the first GLP-1/amylin combo drug on the market.
  • Eli Lilly stock rose 3.1% in premarket trading on the news.

Novo Nordisk took another hit on Monday. The stock fell as much as 15% after the company revealed its next-generation weight loss drug, CagriSema, failed to prove it was just as good as Eli Lilly’s tirzepatide in a head-to-head trial.


NVO Stock Card
Novo Nordisk A/S, NVO

The result sent NVO to its lowest price since June 2021.

In the late-stage trial, patients on CagriSema lost 23% of their body weight over 84 weeks. Those on tirzepatide — the active ingredient in Lilly’s Mounjaro and Zepbound — lost 25.5%.

That gap meant CagriSema missed its primary endpoint: showing non-inferiority to tirzepatide.

The trial was open-label, meaning participants knew which drug they were taking. Novo’s Chief Scientific Officer Martin Holst Lange said this design can introduce bias toward a well-known product when tested against an experimental one.

Advertisement

Lange said he was “surprised” by tirzepatide’s 25.5% result, pointing out that Lilly’s own studies have shown the drug producing around 20.2% weight loss over 72 weeks.

CEO Stays Optimistic

Despite the miss, CEO Mike Doustdar pushed back on the negativity. “We strongly believe that CagriSema has, right now, the best weight efficacy than any product currently in the market,” he said.

Novo filed CagriSema with the FDA late last year, and a decision is expected by late 2026. Doustdar said he expects it to reach the market early next year with the best weight-loss label available.

The company is also exploring additional trials, including higher-dose combinations, to maximize the drug’s potential.

CagriSema combines semaglutide — the ingredient in Ozempic and Wegovy — with cagrilintide, an experimental hormone that affects appetite. Novo has positioned it as the first GLP-1/amylin combination treatment for obesity.

Advertisement

A Rough Run for Novo

This is not an isolated setback. When Novo first released CagriSema late-stage data in December 2024, the stock dropped 21% and wiped out nearly $100 billion in market value.

Over the past year, NVO has lost close to 50% of its value.

Earlier this month, Novo forecast a sales and profit decline of between 5% and 13% for 2026. The company is dealing with rising competition, lower U.S. prices, and upcoming patent expirations on Wegovy and Ozempic in some markets.

Jefferies analyst Michael Leuchten noted that CagriSema’s commercial positioning is “increasingly unclear” following Monday’s results. He estimated the drug could account for 15% to 25% of Novo’s revenue by 2030 and said the situation highlights “the pressing need for M&A,” forecasting Novo could spend up to $35 billion on acquisitions this year.

Meanwhile, Eli Lilly’s stock rose 3.1% in premarket trading Monday.

Advertisement

Novo’s Copenhagen-listed stock was last seen down 14% at 259 Danish kroner.

Source link

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Crypto World

Bittensor (TAO) Crypto Surges 46% as Covenant-72B Launch Triggers Subnet Explosion

Published

on

tao logo

Bittensor (TAO) crypto just surged 46% in March. Trading near $277.

The network successfully deployed its Covenant-72B model on Subnet 3. That is not a roadmap promise. It is a live heavy-compute model running on-chain.

The market responded immediately. The subnet-native τemplar token pumped nearly 200% in under a week.

TAO is no longer just a governance play. Actual utility demand is driving this move.

Advertisement

Key Takeaways:

  • TAO posts 46% monthly gain driven by Covenant-72B model deployment.
  • Subnet 3 activity explodes, pushing the τemplar token up 194% in days.
  • Institutional inflow accelerates ahead of potential Grayscale ETF approval.

Covenant-72B: Why This Release Moved the Market

Covenant-72B is a 72 billion parameter large language model. A significant jump from the lighter models Bittensor has run previously. It means the network can now handle enterprise-grade compute loads.

That scale directly impacts validator staking. Running a model this size requires higher quality miner inputs and more TAO staked to secure the bandwidth. Demand for compute on Subnet 3 created direct demand for the collateral backing it. The pricing mechanism worked exactly as designed.

The biggest winner was not TAO itself. It was τemplar, the Subnet 3 native token, which rallied 194% following the deployment. That is the ecosystem feedback loop in action. High-performance subnets attract speculative capital, which deepens liquidity for the miners running there.

Volume backs the move. TAO’s volume-to-market-cap ratio is sitting between 17% and 19%, with over $254 million traded in 24 hours. That is not a thin order book pump. That is real participation.

When subnet tokens outperform the parent chain like this, it typically signals the start of an application layer season for the protocol. That is the next phase traders are positioning for.

TAO Crypto Price Analysis: Can Bulls Breach $300?

Advertisement

TAO is consolidating at $277.49, just below the $300 psychological level. Structure stays bullish as long as $250 holds.

The 46% impulse already flushed weak hands. OI is building. Traders are positioning for a breakout.

Bittensor (TAO)
24h7d30d1yAll time

Bull case: daily close above $300 opens $350. Grayscale ETF filing provides the fundamental narrative. Volume needs to stay above $250 million daily to keep the momentum alive.

Bear case: rejection at $300 retests $240. If the broader altcoin recovery stalls, TAO could chop sideways for weeks. Watch $265 closely. Lose that level and the immediate breakout setup is invalidated.

Advertisement

The post Bittensor (TAO) Crypto Surges 46% as Covenant-72B Launch Triggers Subnet Explosion appeared first on Cryptonews.

Source link

Advertisement
Continue Reading

Crypto World

Bitcoin ETFs on Track to Turn Positive YTD as XRP Rebounds

Published

on

Bitcoin ETFs on Track to Turn Positive YTD as XRP Rebounds

US spot Bitcoin exchange-traded funds (ETFs) extended their inflow streak to seven consecutive days, marking the longest run since October 2025.

Spot Bitcoin (BTC) ETFs added $199.4 million on Monday, bringing their seven-day streak to around $1.2 billion, according to data from SoSoValue. The latest inflows suggest continued institutional interest, though total inflows remain far below the roughly $6 billion seen during the October 2025 run.

Total trading volumes fell to $2.6 billion on Monday, while total assets under management in Bitcoin ETFs climbed to $96.7 billion. Net year-to-date flows remain negative, following $1.8 billion in cumulative monthly outflows and $1.7 billion in cumulative inflows.

The ETF rebound has coincided with broader strength in crypto investment products, which drew about $2.7 billion over three straight weeks, lifting year-to-date inflows to roughly $1.2 billion, according to CoinShares.

Advertisement
Daily spot Bitcoin ETF inflows from March 9–March 17, 2026, versus Sept. 29–Oct. 9, 2025. Source: SoSoValue

XRP funds post first gains after eight-day losing streak

Spot altcoin ETFs also saw a broad uptick, led by Ether (ETH) with $138.3 million in inflows, the largest since March 4. Solana (SOL) followed the trend with $17.8 million in inflows, also the biggest since March 4.

XRP (XRP) stood out with $4.64 million inflows, the first gains since March 4. The ETFs saw $56.8 million outflows in the period from March 5-16.

Daily XRP ETF flows from March 4–March 17, 2026. Source: SoSoValue

Despite $33.5 million in outflows so far in March, XRP ETFs remain in the green year-to-date, supported by $73.7 million in inflows during January and February.

Solana leads all crypto ETFs year-to-date with $223 million in net inflows.

Related: Bernstein says Bitcoin rebound reflects more resilient long-term holder base

In contrast, Ether ETFs remain underwater, with $364.5 million in year-to-date outflows, following $358.5 million in inflows in March and $723 million in outflows during the first two months of the year.

Advertisement

Magazine: Spot Bitcoin ETFs first green week, crypto ATM losses surge 33%: Hodler’s Digest, Mar. 8 – 14